The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study | Zendy

Anna M.M. van Deursen | Zendy; Marlies A. van Houten | Zendy; Chris Webber | Zendy; Michael A. Patton | Zendy; Daniel A. Scott | Zendy; Scott D. Patterson | Zendy; Qin Jiang | Zendy; William C. Gruber | Zendy; Beate Schmöele-Thoma | Zendy; Diederick E. Grobbee | Zendy; Marc J. M. Bonten | Zendy; Elisabeth A. M. Sanders | Zendy

Open Access

The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study

Author(s) -

Anna M.M. van Deursen,

Marlies A. van Houten,

Chris Webber,

Michael A. Patton,

Daniel A. Scott,

Scott D. Patterson,

Qin Jiang,

William C. Gruber,

Beate Schmöele-Thoma,

Diederick E. Grobbee,

Marc J. M. Bonten,

Elisabeth A. M. Sanders

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy009

Subject(s) - medicine , streptococcus pneumoniae , carriage , pneumococcal conjugate vaccine , haemophilus influenzae , vaccination , moraxella catarrhalis , serotype , pneumonia , microbiology and biotechnology , immunology , antibiotics , biology , pathology

The impact of pneumococcal conjugate vaccination on the prevalence of nasopharyngeal carriage with pneumococci and other bacteria in adults is unknown. The direct effects of the 13-valent pneumococcal conjugate vaccine (PCV13) in community dwelling older adults was investigated as part of the randomized controlled Community Acquired Pneumonia immunization Trial in Adults (CAPiTA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research